Takeda Pharmaceutical (TAK) - Long-Term Debt to Capital

Takeda Pharmaceutical (TAK) efficiency is based on a complex temperature control system for global medication supplies. The company's revenues rely on demand in oncology, gastroenterology, and the rare disease segment. The market valuation trend, recorded at 0.54, coexists with challenges for the Japanese behemoth: massive debts following the Shire deal, regulatory pricing pressure, and the risk of patent expiration.

This ratio assesses long-term financial stability by measuring the proportion of debt with a maturity of over one year relative to equity to determine the degree of leverage. By analyzing the ratio of long-term liabilities to equity, an investor can see how Takeda Pharmaceutical (TAK) balances its debt load amid yen currency fluctuations and geopolitical risks, confirming the business's fundamental ability to service its debt.